section name header

Pronunciation

doo-la-GLOO-tide

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: glucagon like peptide 1 glp 1 receptor agonists

Indications

REMS


Action

  • Acts as an acylated human glucagon-like peptide-1 (GLP-1, an incretin) receptor agonist; increases intracellular cyclic AMP (cAMP) leading to insulin release when glucose is elevated, which then subsides as blood glucose decreases toward euglycemia. Also decreases glucagon secretion and delays gastric emptying.
Therapeutic effects:
  • Improved glycemic control.
  • Reduction in risk of cardiovascular death, nonfatal MI, or nonfatal stroke.

Pharmacokinetics

Absorption: 0.75 mg dose: 65% absorbed following SUBQ administration; 1.5 mg dose: 47% absorbed following SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Degraded by protein catabolic processes.

Half-Life: 5 days.

Time/Action Profile

( in A1c)
ROUTEONSETPEAKDURATION
SUBQwithin 4 wk13 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Type 2 Diabetes

Risk Reduction of Major Cardiovascular Events

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Trulicity